Pharmacosmos has entered into an exclusive licensing agreement with SteinCares, one of Latin America's leading specialty healthcare companies, to commercialize and distribute Monofer® (ferric derisomaltose), a high-dose IV iron which is indicated, in the EU, for the treatment of iron deficiency (ID) when oral iron preparations are ineffective or cannot be used; or where there is a clinical need to deliver iron rapidly.
"We are very excited about this partnership with Pharmacosmos, a leading international company that specializes in IV iron treatments. Monofer® will provide patients in the region with an innovative and cost-efficient treatment option for iron deficiency anemia. In addition, this agreement reinforces our position as a strategic partner for global pharmaceutical companies that bet on Latin America", stated Sebastian Katz, Chief Strategy Officer at SteinCares.
Claes C Strom, Chief Commercial Officer at Pharmacosmos also commented on his enthusiasm for the signing of this deal. "This agreement represents an important milestone as Latin America is a market with great potential. We are confident that SteinCares' strong track record in hematology and nephrology, combined with our company’s expertise in IV iron treatments, will provide an excellent platform for Monofer® in the region”.
SteinCares is a leader in commercializing and distributing specialty healthcare products in Latin America, including innovative pharmaceuticals, biosimilars and complex generics. With more than 40 years of progressive healthcare experience and presence in more than 30 countries in Latin America and the Caribbean, SteinCares serves as a bridge between the world’s pharmaceutical companies and the region’s wellness providers.
The company is highly committed to creating healthcare opportunities that positively impact the lives of patients and their families in Latin America, as it has the vision to give more access to innovative and cost-effective healthcare to patients in the region.
For more information, visit www.steincares.com.
Marketing and Corporate Communications Manager
+54 911 6367 1612, email@example.com
Christian Lundquist Madsen
Head of Global Marketing
+45 5948 5959, firstname.lastname@example.org
Pharmacosmos Group, headquartered in Holbaek, Denmark, and founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia. With companies in the UK, Nordics, Germany, the USA, and China, as well as through partners, Pharmacosmos markets its products around the world. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with deep expertise in the synthesis of iron-carbohydrate complexes. The Pharmacosmos Group has more than 500 employees.
You are now leaving Pharmacosmos.com. The website you are about to visit is a Pharmacosmos subsidary.
Do you wish to proceed?